InvestorsHub Logo
Followers 75
Posts 4656
Boards Moderated 0
Alias Born 09/06/2003

Re: soma2022 post# 5013

Tuesday, 11/07/2023 9:00:21 PM

Tuesday, November 07, 2023 9:00:21 PM

Post# of 7411

what am I missing guys? Please walk me through the graphs they presented at ASDS



Most of us cannot see the graphs, only the PR etc, which is very vague. (See below). And companies in this space have a tendency to game metrics is a wide variety of ways. Eg look at duration only in good responders. Revance does this kind of thing too - eg look at two metrics (patient and physician) and for each patient choose the best. The only way to detect the specific form of gaming is to have a complete package and go through it in detail. And note - the fact that they claim “AE profile is similar across all three arms’ seems implausible. My guess is there is a meaningful increase, but, for example, they defined categories to be small enough that it’s not stat sig in any given category (by breaking it up into categories you make it much harder to be stat sig)


Results demonstrated 26 weeks, or 6 months duration across the multiple metrics presented, including the time it took for patients to return to their baseline GLS score after their treatment, the duration of effect for a patient with at least a one-point GLS improvement, and the time it took a patient to return to their baseline using the Global Aesthetic Improvement Scale.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News